DRL to market and distribute Amgen’s Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India
Dr Reddy’s Laboratories (DRL) has expanded its strategic collaboration with US-based independent biotechnology firm Amgen to market and distribute in India three... Read More
Strategic Deal : Amgen Regain Rights of Prolia, Xgeva & Vectibix brands from Glaxo
About the deal: Amgen has entered into a definitive agreement with GlaxoSmithKline plc. Under this agreement, Amgen will regain all remaining rights... Read More
Amgen’s Xgeva gets US FDA approval to treat hypercalcemia of malignancy refractory to bisphosphonate therapy
Amgen  today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment... Read More